One gene helps drive growth in two childhood brain tumor groups that lack targeted therapies
Targeting KDM2B or downstream protein complexes it recruits may exploit a vulnerability in high-risk medulloblastoma subgroups that currently lack targeted therapies, according to a study led by St. Jude Children's Research Hospital and Hopp Children's Cancer Center Heidelberg (KiTZ). The researchers found that Group 3 and Group 4 medulloblastomas depend on the protein KDM2B for growth and that…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Chronic postsurgical pain affects women long after cesarean delivery
-
Blood proteins may help monitor Alzheimer’s treatment response
-
Intuitive eating may be linked to more than a healthier relationship with food
-
Neuromedin U drives immune suppression in aggressive prostate cancer
-
Scientists gave worms magnetic bacteria. They lived 43% longer
-
Why are more younger adults in the Eastern Mediterranean facing colorectal cancer?
-
USP15 enzyme emerges as potential target for ovarian cancer treatment
-
Uterus transplantation shows improving outcomes and successful births nationwide